A Phase III Study of NK105 in Patients With Breast Cancer

NCT01644890 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

436

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer Nos Metastatic Recurrent

Interventions

DRUG: NK105
DRUG: Paclitaxel

Sponsor

Nippon Kayaku Co., Ltd.